New schizophrenia drug shows promise in early trial
NCT ID NCT06442462
First seen Feb 06, 2026 · Last updated May 03, 2026 · Updated 5 times
Summary
This study tests an experimental drug called SPG302 in 32 adults with schizophrenia to see if it can reduce symptoms like hallucinations and disorganized thinking. Participants take the drug or a placebo for a set time, and researchers measure changes in symptom severity, brain activity, and eye movements. The goal is to find a safer, more effective treatment option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Box Hill Hospital - Eastern Health
Box Hill, Victoria, 3128, Australia
-
CenExel CNS
Garden Grove, California, 92845, United States
-
Multidisciplinary Alfred Psychiatry Research Centre (MAPrc)
Melbourne, Victoria, 3004, Australia
Conditions
Explore the condition pages connected to this study.